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Background/Aims
GC7101, an extract of Lonicera Flos, is a novel developing drug for reflux esophagitis and functional dyspepsia. However, the 
drug’s exact pharmacological mechanism of action remains unclear. This study assessed the effects of GC7101 on gastro-
intestinal (GI) motor function.
Methods
We used male guinea pigs to evaluate the effects of GC7101 on GI motility. The contraction of antral circular muscle in the 
presence of different doses of GC7101 was measured in a tissue bath. The prokinetic effects of GC7101 were tested using the 
charcoal transit assay from the pylorus to the most distal point of migration of charcoal mixture. To clarify the mechanism of 
action of GC7101, atropine, dopamine and the selective 5-hydroxytryptamine 4 receptor antagonist, GR113808 were used.
Results
The maximal amplitude of circular muscle contraction was induced by 5 mg mL−1 GC7101. The area under the curve of con-
traction was significantly increased at 5 mg mL−1 GC7101. Addition of 10−6 M atropine, 10−8 M dopamine or 10−7 M GR 
113808 to GC7101 5 mg mL−1 decreased the amplitude and area under curve compared to GC7101 5 mg mL−1 alone. 
GC7101 accelerated GI transit in a dose dependent manner except 100 mg kg−1. Delayed GI transit caused by atropine, dop-
amine and GR 113808 was restored by GC7101 50 mg kg−1.
Conclusions
GC7101, an extract of Lonicera Flos, exerts a gastric prokinetic effect in guinea pig through cholinergic, antidopaminergic and 
serotonergic mechanisms. Therefore, GC7101 might be a novel drug for the treatment of functional dyspepsia.
(J Neurogastroenterol Motil 2014;20:469-474)
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Introduction
Functional dyspepsia (FD) is one of the most common gas-
trointestinal (GI) disorders, which is defined as occurrence of up-
per abdominal symptoms without organic causes.1 The preva-
lence of FD defined according to strict criteria is about 5-12%.2 
The pathophysiology of FD is complex, with multiple factors im-
plicated; however, abnormalities in GI motor function have been 
proposed as a major cause of FD. Abnormal gastric motility and 
visceral hypersensitivity are 2 major physiological abnormalities 
that cause FD. Other diverse factors such as genetic predis-
position, a prior viral infection, stress, inflammation, Helicobacter 
pylori infection, abnormal secretion of gastric acid, psychological 
factors, diet and lifestyle could affect the pathogenesis of FD.3 
Although FD is a very common disorder, it is difficult to manage. 
Among the medications used to treat FD, prokinetics have 
shown efficacy in meta-analyses.4 However, the reliability of 
these studies is very low and the adverse effects of previous proki-
netics were serious. Therefore, new drugs for the treatment of 
FD including mosapride, itopride and acotinamide have been de-
veloped, which show improvements of GI motility without ad-
verse cardiovascular events.5 In this respect, the need of safer and 
more effective medications for the treatment of FD has increased. 
Thus, several herbal medicines were assessed for their potential to 
treat FD.6 For example, DA-9701, an extract from 2 herbs 
(Pharbitis Semen and Corydalis Tuber) has been reported to ac-
celerate gastric emptying in normal rats and restore delayed 
emptying. DA-9701 also increased GI transit in controls and de-
layed gastric emptying models induced by laparotomy or 
atropine.7 In addition, Kim et al8 showed that DA-9701 im-
proved gastric accommodation by increasing the postprandial 
gastric volume in conscious dogs. At least 44 herbal products 
have been recommended for treatment of FD.6 A large number 
of herbal medicine clinical trials showed that patients receiving 
peppermint and caraway had improved symptoms by 60-95%.9 
GC7101 is a potential prokinetic agent which was obtained from 
extracts of Lonicera Flos (LF). It is a widely used herbal medi-
cation in China and is known to have latent-heat-clearing, anti-
pyretic, antioxidant and anti-inflammatory actions.10 Ku et al11 re-
ported that the antioxidant properties of LF were effective in gas-
troesophageal reflux disease. They found that LF combated oxi-
dative stress and free radical damage in esophageal and gastric 
mucosa in rat models.11 In addition, they found that LF pro-
moted gastric motor function (unpublished data). There are no 
previous reports on the effects of LF on GI motor function. 
Therefore, we aimed to investigate the prokinetic effect of 
GC7101 on GI contraction and transit and to validate which 
mechanisms GC7101 exerts through ex vivo.
Materials and Methods
Preparation of Animals
Adult male Hartley guinea pigs (250-350 g, Orient Bio Inc., 
Seoul, Korea) were acclimated to their holding room (temper-
ature controlled at 21 ± 1oC, 50 ± 10% humidity, and 12 hour 
light/dark cycle commencing at 7 AM). A standard guinea pig 
diet (7006 Teklad Guinea Pig Diet; Harlan laboratories) and 
drinking water were provided ad libitum. All experiments were 
conducted in accordance with the Guide for the Care and Use of 
Laboratory Animals provided by the Animal Laboratory Ethics 
Committee of the Department of Laboratory Animal Medicine, 
Medical Research Center, Yonsei University College of Medicine.
Drugs
The following drugs and chemicals were used; charcoal 
(Sigma, St. Louis, MO, USA), barium sulfate (Tae Joon 
Pharmaceuticals, Seoul, Korea), GC7101 (Green cross Corp, 
Yongin, Korea), atropine and dopamine (Sigma, St. Louis, MO, 
USA), and  GR113808 (Tocris, Ellisville, MO, USA). They 
were freshly made for every experiment by dissolving each com-
pound in isotonic sodium chloride solution. 
Experimental Design: The Effects of GC7101 
on Antral Circular Muscle Contraction
Antral circular muscle was removed and cut into 3-mm wide 
and 10-mm long fragments and the lumen flushed clean using 
Krebs-Henseleit (K-H) solution which was maintained at 37oC, 
pH 7.4 and saturated with 95% O2 and 5% CO2 in a chamber. 
The circular muscle was fixed and connected to independent ten-
sion transducers (BIOPAC TSD 105; BIOPAC Systems, Inc., 
Santa Barbara, CA, USA). The preparation was set up and al-
lowed to equilibrate for at least 60 minutes after 1 g resting 
tension. Circular muscle activity was quantified by means of a 
computerized integration procedure (BIOPAC MP 100; 
BIOPAC Systems, Inc.). GC7101 (0.01-10 mg mL−1) was add-
ed to the bath solution for 5 minutes without washing between 
successive changes in concentration. Drugs including GC7101, 
atropine, dopamine and GR113808, a selective 5-hydroxytrypt-
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Figure 1. Effects of GC7101 on contraction of stomach antral muscle. GC7101 increased maximal amplitude and area under the curve in a dose 
dependent manner (0.1-10 mg mL-1). (A) Maximal amplitude (% control). *P = 0.010, **P ＜ 0.001 compared with control levels. (B) Area under 
the curve (% control). *P = 0.010, **P ＜ 0.001 and ***P = 0.001 compared with control levels. Values are mean ± SE. 
Figure 2. Effects of atropine, dopamine, and GR113808 on contrac-
tion of GC7101-treated stomach antral muscle. Addition of 10-6 M 
atropine, 10-8 M dopamine or 10-7 M GR113808 to GC7101 5 mg 
mL-1 decreased the amplitude of contraction with GC7101 alone.  
Values are mean ± SE.
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Figure 3. The effects of GC7101 assessed by migration of charcoal. 
GC7101 accelerated gastrointestinal transit of charcoal in a dose 
dependent manner except 100 mg kg−1. Values are mean ± SE.
amine 4 (5-HT4) receptor antagonist, were added to the chamber. 
The maximal amplitude and area under the curve (AUC) of the 
antral muscle contraction were obtained to evaluate the effects of 
drugs on GI motility.
Experimental Design: The Effects of GC7101 
on Charcoal Transit
After being fasted for 24 hours with free access to water, guin-
ea pigs received atropine 0.1 mg kg−1, dopamine 0.4 mg kg−1 or 
GR 113808 1 mg kg−1 via orogastric cannula. After 30 minutes, 
GC7101 was administered via orogastric cannula, followed by 
2.5 mL of a charcoal mixture after another 30 minute wait. The 
charcoal mixture consisted of charcoal, barium, and normal saline 
in a 1:2:6 ratio. The guinea pigs were sacrificed by blow to the oc-
cipital region and severing the carotid arteries. The abdomens 
were opened and the intestines were removed from the pyloric 
junction to the ileocecal valve. Upper GI transit was evaluated as 
the migration of charcoal mixture from the pylorus to the most 
distal point of migration, and expressed as a percentage (%) of 
charcoal migration (cm) to the length of total small intestine (cm) 
5 minutes after injection of the charcoal mixture.
Statistical Methods
Results for each variable were expressed as percentage of con-
trol levels. Statistical analysis was performed using repeated meas-
ures ANOVA with post hoc comparison or the Mann-Whitney U 
test. In all tests, statistical significance was assigned if P ＜ 0.05 
based on the mean. Values are means with standard error. All da-
ta were analyzed using SPSS version 12.0 for Windows software 
(SPSS Inc., Chicago, IL, USA).
Results
Effects of GC7101 on Contraction of 
Stomach Antral Muscle
The amplitude of circular muscle contraction increased in a 
dose dependent manner from 0.1 to 5 mg mL−1 (except 10 mg 
mL−1) GC7101. The maximal amplitude of the circular muscle 
contractions were 221.4 ± 49.7%, 315.7 ± 76.4%, 338.5 ± 
80.2%, 396.8 ± 89.2% and 324.9 ± 94.2% in the presence of 
0.1, 0.5, 1, 5 and 10 mg mL−1 GC7101, respectively. The max-
imal amplitude of the circular muscle contraction was induced by 
5 mg mL−1 GC7101 (Fig. 1A). The AUC of the circular muscle 
contraction also increased in a dose dependent manner with 0.1 to 
5 mg mL−1 (except 10 mg mL−1) GC7101. The AUC of the 
circular muscle contractions were 190.2 ± 32.4%, 282.8 ± 
56.3%, 312.8 ± 57.9%, 373.3 ± 58.4% and 339.2 ± 84.4% in 
the presence of 0.1, 0.5, 1, 5 and 10 mg mL−1 GC7101, 
respectively. The maximal AUC of the circular muscle con-
traction was induced by 5 mg mL−1 GC7101 (Fig. 1B). 
Addition of 10−6 M atropine, 10−8 M dopamine, or 10−7 M GR 
113808 to GC7101 5 mg mL−1 decreased the amplitude com-
pared to GC7101 alone (228.4 ± 48.5% vs. 171.5 ± 38.1%, P = 
0.046;  228.4 ± 40.3% vs. 202.6 ± 36.8%, P = 0.043; 157.6 ± 
26.3% vs. 141.3 ± 24.7%, P = 0.043; respectively) (Fig. 2). 
Effects of GC7101 on the Transit of 
Charcoal
The average charcoal transit was 35.1 ± 5.6% in the control 
group. The percentage (%) of the migration length (cm) of char-
coal to total small intestine (cm) was 46.4 ± 7.9%, 55.9 ± 4.1% 
and 20.1 ± 6.8% in 25 mg kg−1, 50 mg kg−1 and 100 mg kg−1 
GC7101, respectively (P = 0.002). In normal guinea pigs, 
GC7101 accelerated GI transit of charcoal in a dose dependent 
manner except the 100 mg kg−1 dose. The maximal charcoal 
transit was induced by 50 mg kg−1 GC7101 (P = 0.030 com-
pared to the control). However, the charcoal transit slightly de-
creased with 100 mg kg−1 GC7101 (Fig. 3). Subsequently, we 
used the delayed model of GI transit to assess whether GC7101 is 
able to reverse abnormally delayed GI transit. Delayed charcoal 
transit after administration of atropine 0.1 mg kg−1, dopamine 
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Figure 4. The effects of GC7101 on altered gastrointestinal transit 
induced by atropine, dopamine or GR113808. Delayed charcoal 
transit after administration of atropine or dopamine was restored by 
GC7101 at 50 mg kg-1. Values are mean ± SE.
0.4 mg kg−1 or GR113808 1 mg kg−1 was restored by GC7101 
at a dose of 50 mg kg−1 (Fig. 4). These results showed that 
GC7101 not only accelerated GI transit in normal conditions, but 
furthermore restored delayed GI transit induced by atropine, 
dopamine or GR113808.
Discussion
FD is a chronic and highly prevalent GI disorder that im-
poses a large amount of healthcare cost on patients. Therefore, 
many studies are ongoing to identify therapeutic agents for FD. 
Prokinetics are known to be helpful for relieving the symptoms of 
FD. However, their application is very limited due to several fac-
tors including ineffectiveness and potentially fatal side effects. As 
the demands of more safe and effective medications for FD in-
creased, several herbal medicines have been evaluated for their 
potential use. GC7101 is an extract of LF which is a widely pre-
scribed herbal medicine in China. However, the pharmacological 
effects of LF on GI motor function have not been studied yet. 
There was one report that application of the Chinese herbal recipe 
composed of multiple plants and roots including LF could effec-
tively promote postoperative recovery of GI motility.12 For the 
first time, we showed that GC7101 has effects on GI motor func-
tion assessed by gastric antral contraction and GI transit. It im-
plies that GC7101 is a potential candidate to treat FD with de-
layed gastric emptying. GI transit and gastric antral contraction 
are well established models to assess prokinetic effects. Atropine 
has inhibitory effects on GI motility by acting as a competitive an-
tagonist of the acetylcholine receptors. Dopamine and GR 
113808 also delay GI motility through dopamine receptors and 
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antagonism of 5-HT4-receptors, respectively. Dopamine de-
creases motility of the GI tract, whereas dopamine antagonists in-
crease peristaltic contraction of the esophageal muscles and im-
prove GI motor activity.13 Selective 5-HT4 receptor agonists has 
been shown to enhance gastric accommodation and accelerate 
gastric emptying and GI transit.14 GC7101 could restore the de-
layed GI transit caused by atropine, dopamine, or GR113808. 
The increased contraction by GC7101 was inhibited by atropine, 
dopamine, or GR113808. Taken together, GC7101 enhances GI 
motor function by acting on cholinergic, antidopaminergic, and 
serotonergic mechanisms. These results showed that GC7101 
could enhance GI motility both in normal or abnormal conditions 
and identify a possible novel therapeutic agent of FD. 
In conclusion, GC7101 which is an extract from LF, exerts a 
gastric prokinetic effect in guinea pigs through multiple mecha-
nisms including cholinergic, antidopaminergic and serotonergic 
mechanism. Further studies are definitely warranted to prove the 
therapeutic use of GC7101 in FD through highly qualified and 
controlled clinical trials. 
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